Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
November 12, 2019Conducting Phase 3 trial for NRX-101, an FDA-designated Breakthrough Therapy for Suicidal Bipolar DepressionWILMINGTON, DE - November 12, 2019 / NeuroRx, Inc. (NeuroRx) a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it will...
-
October 23, 2019
NeuroRx, Inc (NeuroRx) announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York based private alternative investment group to provide the NeuroRx with up to...
-
September 9, 2019
NeuroRX, a phase 3 biopharma company focused on development of NRX-101, an FDA-designated Breakthrough Therapy for Severe Bipolar Depression with Acute Suicidal Ideation, will present a corporate...
-
July 9, 2019Pivotal study will test novel, oral antidepressant in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation & Behavior following initial stabilization with ketamine
NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it has initiated a pivotal Phase 2b/3 study for NRX-101...
-
June 3, 2019First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation
NeuroRX, a clinical-stage biopharma company developing the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation or Behavior, will present phase 2 efficacy results from its...
Click here to view our corporate presentation or on the image below
 |
